Brief: TCR2 Therapeutics Reports Fourth Quarter 2021 Financial Results
22/03/2022 11:30
March 22 (Reuters) - TCR2 Therapeutics Inc TCRR.O :
* TCR² THERAPEUTICS REPORTS FOURTH QUARTER 2021 FINANCIAL
RESULTS
AND PROVIDES CORPORATE UPDATE
* EXPECT CASH ON HAND TO SUPPORT OPERATIONS INTO 2024
* QTRLY NET LOSS PER SHARE OF COMMON STOCK, BASIC AND
DILUTED
$0.72
* Q4 EARNINGS PER SHARE VIEW $-0.75 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX4Vq9xx
Further company coverage: TCRR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TCR2 Therapeutics
See all newsBrief: TCR2 Therapeutics Entered Into An Assignment Of Lease Agreement With Astrazeneca
TCR2 Therapeutics falls on bigger-than-expected Q1 loss
Brief: Tcr² Therapeutics Reports Q1 2023 Financial Results And Provides Corporate Update
TCR2 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
TCR2 Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview